Sistema PJSFC

  • Land: Russland

Nachricht vom 15.09.2021 | 18:30

Sistema PJSFC: Announcement on the acquisition of Nearmedic Group

Sistema PJSFC (SSA)
15-Sep-2021 / 19:30 MSK
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

15 September 2021, Moscow - Sistema PJSFC ("Sistema", the "Corporation" or, together with its subsidiaries and affiliates, the "Group") (LSE: SSA, MOEX: AFKS) announces that JSC New Investment Holdingi ("the Buyer") has acquired Nearmedic International Limited, the 100% shareholder of LLC Nearmedic Plus, LLC Nearmedic Pharma, and several other pharmaceutical, biotech, and healthcare businesses in Russia and Italy ("Nearmedic Group" or "Nearmedic") for 1 rouble ("the Transaction"). Nearmedic Group's net debt as of the closing of the Transaction was RUB 5.9bn. 
Sistema and the Sberbank group of companies ("Sberbank") have in equal parts provided the Buyer with RUB 1.2bn in equity financing that will go towards the partial repayment of Nearmedic's outstanding debt to Sberbank. Sistema and Sberbank have also entered into option agreements, exercisable within 3.5 years from the date of closing, enabling Sistema to buy and Sberbank to sell to Sistema its equity interest in JSC New Investment Holding, with up to RUB 2.8bn in outstanding receivables due from Nearmedic to be transferred from Sberbank to Sistema immediately upon such sale.
"Nearmedic Group has growth potential that can be unlocked through restructuring and improvements in efficiency, areas precisely where Sistema has robust, proven expertise. We also have a strong track record in pharmaceuticals, healthcare and biotech, all of which are key business lines for Nearmedic. We will shortly begin implementing a turnaround plan for Nearmedic Group focused on boosting the value of the company's assets and expanding production capacities," said Sistema President Vladimir Chirakhov. 
Nearmedic Group consists of pharmaceutical, biotech, and medical assets. The company's core businesses are the design and production of original medications; the development, manufacturing and sale of diagnostic test kits; the supply of suites of equipment for medical laboratories; and the provision of medical and lab services.
Nearmedic Group possesses production facilities in the cities of Obninsk and Mosalsk, a factory producing medical products in Italy, and a chain of multi-specialty medical clinics across Moscow, Obninsk, and Ryazan.
***
For further information, please visit www.sistema.com or contact:
Public Relations
Sergey Kopytov
Phone: +7 (495) 228 15 32
kopytov@sistema.ru
Investor Relations
Nikolai Minashin
Phone: +7 (495) 730 66 00
n.minashin@sistema.ru

 
 
Sistema PJSFC is a publicly traded Russian investment company with a diversified portfolio of assets serving some 150 million customers in the sectors of telecommunications, high technology, financial services, retail, paper and packaging, agriculture, real estate, tourism and medical services. The company was founded in 1993. Revenue in 2020 was RUB 691.6 billion; total assets equalled RUB 1.4 trillion as of 31 December 2020. Sistema's global depositary receipts are listed under the "SSA" ticker on the London Stock Exchange. Sistema's ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange. Website: www.sistema.com
 
(i) JSC New Investment Holding is jointly controlled by the Group and Sberbank, which own 50%+1 shares and 50%-1 shares in its equity, respectively.



show this

Interview im Fokus

„Eine Investition in Mutares lohnt sich“

Mutares ist ein europaweit führender Private-Equity-Investor, der sich auf Sondersituationen wie Abspaltungen von großen Konzernen oder Turnaround- und Nachfolgesituationen spezialisiert hat. Ziel ist es, mit den Investments einen Return auf das eingesetzte Kapital von 7 bis 10 zu erzielen. Mit der jüngsten Mittelfristprognose hat der Münchner Finanzinvestor auf Basis von 5 Mrd. Euro Konzernumsatz eine Nettorendite für die börsennotierte Holding von 1,8 bis 2,2 % in Aussicht gestellt. In der Mitte der Zielspanne wird somit ein Nettogewinn von circa 100 Mio. Euro anvisiert. Hauck & Aufhäuser hat in der jüngsten Analyse ein Buy-Rating mit Kursziel für Mutares von 37,50 Euro ausgegeben.

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Vonovia on the election of the Berlin House of Representatives and the referendum to expropriate Deutsche Wohnen & Co.: Berlin needs a new way of working together on housing

27. September 2021, 11:07

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

CLIQ Digital AG

Original-Research: CLIQ Digital AG (von Montega AG): Kaufen

27. September 2021